FDC Limited (531599) Fair Value & Analysis

Healthcare · IN · Market cap ₹59.4B

A solid business, but screening 28% overvalued on our models.

What matters now

• A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
• The price sits above even our optimistic bull case (₹339.74). The favourable scenario is already priced in.
• A fairly wide model range (₹156.76 to ₹339.74) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 18, 2026.

How to read this chart

60‑month range ₹225.45 – ₹598.46 · fair‑value band ₹156.76 – ₹339.74 · the ₹354.40 price screens above the ₹255.06 fair value. Dashed = 300-day average. As of Aug 18, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

FDC Limited (531599) currently trades at ₹354.40, while our model-based Fair Value estimate is ₹255.06, implying the stock looks roughly 28.0% overvalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, FDC Limited generated revenue of ₹13.3B at a net margin of 23.2%. Revenue grew 7.3% year over year. It earns a return on equity of 19.6%. The stock trades on a trailing P/E of 18.5 (as of Aug 18, 2026). Fundamentals as of Aug 18, 2026

Our scenario range runs from ₹156.76 (bear case) to ₹339.74 (bull case); at ₹354.40, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 32% below its 52-week high and 13% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -38% fair-value upside, at -28%, 531599 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (₹274.78) versus Dividend Discount (₹77.37). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and …

Full company description

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl-LBW, Simyl-MCT, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. FDC Limited was founded in 1936 and is headquartered in Mumbai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

FDC Limited reported revenue of ₹21.1B in FY2025 versus ₹13.3B in FY2021, a compound +12.1%/yr. Reported net income was ₹2.7B in FY2025, compounding −3.0%/yr from FY2021.

531599 screens 28% overvalued. Compare with AstraZeneca Pharma India Limited →

Peer Group

Health Care · 2250 stocks

How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drug Manufacturers - Major” was too small, so the broader sector is used.)

Valuation Multiples vs Health Care median · lower = cheaper

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate (as of Aug 18, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.